Anand Mahindra, chairperson of Mahindra and Mahindra, recently expressed his excitement over Elon Musk’s latest innovation in neurotechnology, the Blindsight device from Neuralink. On September 19, Mahindra took to X (formerly known as Twitter) to share Musk’s post about the groundbreaking device, stating, “If this device lives up to these expectations then, much more than Tesla or SpaceX, THIS will be your most enduring gift to humankind.”
Musk’s announcement on September 18 outlined the remarkable potential of the Blindsight device, which aims to restore vision to individuals with various forms of blindness. According to Musk, the device could enable even those who have lost both eyes and their optic nerve to see again, provided their visual cortex remains intact. He noted that it could also allow those who have been blind since birth to experience sight for the first time.
While the initial visual output is expected to be low-resolution—comparable to “Atari graphics”—Musk envisions that future developments could yield capabilities that surpass natural vision, including the ability to see in infrared, ultraviolet, and even radar wavelengths, akin to the fictional character Geordi La Forge from “Star Trek.”
The Blindsight device has received a “Breakthrough Device” designation from the U.S. Food and Drug Administration (FDA), which is awarded to medical devices that demonstrate significant promise in treating serious conditions. This designation allows for expedited development and review processes, accelerating the journey towards potential clinical applications.
Despite its ambitious goals, the device remains in the experimental stages and has not yet been approved for commercial use. However, the excitement surrounding it reflects a growing interest in the possibilities of neurotechnology to transform lives.
As advancements continue, many are watching closely to see if Neuralink can deliver on its promise to change the landscape of vision restoration and redefine what is possible for those living with blindness.